Genomic immune evasion mechanisms (e.g., B2M mutations, HLA deletions) are relatively frequent in primary tumors31,32 and indirect evidence suggests their occurrence early during tumor evolution33, but this has never been shown directly. This evidence concerns the gene B2M and neoplasm.